Welcome to Oxford Medical
Diagnostics
Company Presentation
Table of Contents
1
Background
7
Management
2
Opportunities
8
Science Advisory Board
3
Technologies
9
4
Product Strategy & Services
10
Development & Commercial
Partners
Offices
5
Target Markets
11
Contact Details
6
Directors
Background
A merger of:
 EV (Medical Screening) –
original company
 Oxford Medical Diagnostics –
a former company from the University
of Oxford
 Broadband Cavity Enhanced
Absorption Spectroscopy
Background
 Oxford Medical Diagnostics
specialises in the analysis of breath
and industrial gases.
 The Company is developing its
patented sensitive and non-invasive
methods for the diagnosis of medical
conditions by breath analysis.
 It also has leading knowledge and
experience in the detection of gases
for industrial applications.
Historical
Background :
Linus Pauling 1901 - 1994
 An American chemist, peace activist,
author, and educator.
 One of the most influential chemists in
history and ranks among the most
important scientists of the 20th
century.
 One of the key pioneers of modern
breath analysis in the 1970s.
Opportunities
:
Detection of Breath Biomarkers
 Ammonia – renal diseases
 Ethane – lipid peroxidation
 Nitric Oxide – asthma and
pulmonary diseases
 Methane – colonic fermentation
and bacterial overgrowth
 Acetone – Type I and Type II
diabetes
Opportunities :Breath Acetone as a Marker for Diabetes
 Acetone is a marker for the process
of ‘ketogenesis’.
 It involves the break down of body fat
to release energy.
 This process produces acetone - a
volatile, highly blood soluble gas,
exchanged in the airways.
 The ability to detect breath acetone
provides a key means for the
diagnosis and management of
diabetes.
Opportunities :Industrial Gas Analysis
 The requirement to analyse industrial
gases is ubiquitous across a number
of major sectors.
 Oxford Medical Diagnostics has a
range of expertise available for
collaborations in Industrial Gas
Analysis.
 Current target gases include:
• Carbon Dioxide • Methane
• Hydrogen
Sulfide
• Nitrous Oxide
• Sulfur Dioxide
• Acetylene
Technologies
 Plasma Emission Spectroscopy
(PES)
 Cavity Enhanced Absorption
Spectroscopy (CEAS)
 Broadband Cavity Enhanced
Absorption Spectroscopy (BB-CEAS)
 Wavelength Modulation
Spectroscopy (WMS)
Technologies :Plasma Emissions Spectroscopy
 Plasma Emission Spectroscopy
(PES) involves the study of light
emitted from a high voltage plasma
discharge.
 The discharge is just a few mm
across but provides sufficient energy
to excite and fragment molecules
giving rise to characteristic spectra.
 Our studies are focused on the visible
and near-UV region of the spectrum.
Technologies
:
Plasma Emission Spectrum of
Acetone
Technologies
:
Cavity Enhanced Absorption Spectroscopy
 All molecules absorb light at
characteristic frequencies, allowing
spectroscopy to be used for
identification and quantification.
 CEAS utilises two highly-reflective
mirrors to give a pathlength of
kilometres in a bench-top setup, thus
increasing the detection sensitivity.
 CEAS can be coupled with a
broadband (BB) source to resolve the
large spectral features observed in
acetone.
Technologies
:
Cavity Enhanced Absorption Spectroscopy
The sensitivity of laser absorption spectroscopy is also limited by noise. This can be
reduced by using Wavelength Modulation Spectroscopy (WMS) to move the detection
frequency to a less noisy region and thereby increasing the signal to noise ratio.
Product Strategy
The Company is developing products for
two
key areas of the diabetes market:
 Screening – A bench-top device,
based on CEAS technology, for the
rapid and cost-effective screening of
diabetes and pre-diabetic stages.
 Monitoring – A handheld device,
based on PES technology, for the lowcost, daily monitoring of diabetes. The
device could also be used by healthy
individuals looking to monitor ‘fatburning’ through exercise or dieting.
Services
 Ion Molecule Reaction Mass
Spectrometry (IMR-MS) – A pay for
service technique, in conjunction with
V&F GmbH, which utilises a soft
ionisation method to allow the
accurate measurement of constituents
in a gaseous sample.
 Collaborations – Opportunities are
available in both the Clinical and
Industrial Gas Analysis sectors for
exclusive commercialisation by
partners.
Target Markets
 More than 220 million people worldwide
have diabetes. This is expected to
double by 2030 without intervention.
 Whilst the press headlines focus on
‘adult onset’ Type II diabetes, the fastest
rising category in percentage terms is
Type I diabetes in children.
 The daily drawing of blood required for
diabetes monitoring is often dreaded by
children. A non-invasive alternative
would therefore be welcomed by
clinicians, parents and their children
alike.
Target Market
Screening, Diagnosis & Monitoring
Global Market
£4.6 billion
Routes to Market Current Global Medical Diagnostic
Companies
:
Medical Diagnostics
Medical Instrumentation
Health Retail
Directors
Chairman
John Jack (former director IBM
UK)
Non-executive
Seamus Grealish
CEO
Tony Marchington (former
Oxford Molecular)
Non-executive
Michael O’Higgins
CSO
Gus Hancock, Professor of
Chemistry, University of Oxford
Non-executive
Peter Copping
Management
Company Secretary
Rowland Smith
Engineer
John Couper
Science Director
Dr. Robert Peverall
PES Development
Tom Blaikie
Senior Chemist
Dr. Grant Ritchie
BB-CEAS Development
David Taylor
Science Advisory Panel
Prof Gus Hancock, Director of Science & Chairman of the
Science Advisory Panel
Gus Hancock is Professor of Chemistry, University of Oxford and
expert on CEAS and Broadband technologies.
Dr. Grant Ritchie – University of Oxford
Dr. Ewan Bell – Dumfries & Galloway NHS
Trust
Prof. Fran Ashcroft – University of Oxford
Prof. Albert Crowe – University of
Newcastle
Development & Commercial Partners
Avacta Group plc
Uniscan Instruments
V&F Analyse und
Messtechnik GmbH
Ocean Optics
Dumfries & Galloway
Royal Infirmary
University of Oxford
Offices
The company trades from:
 The Oxford University
Begbroke Science
Park, Sandy Lane,
Yarnton, Oxford. OX5
1PF
 INEX, Herschel
Building, University of
Newcastle, Newcastle
upon Tyne. NE1 7RU
Contact Details
To learn more about the Company’s
technologies, products and services, or to
explore the potential for partnership or
collaboration please contact:
 Telephone: + 44 (0) 1865 854 888
 E-mail: info@omdiagnostics.com
 Website: www.omdiagnostics.com